Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLOSSOM: Anifrolumab in Pediatric Moderate to Severe Systemic Lupus Erythematosus
jRCT2031240525Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Anifrolumab with Placebo (2 arms). Primary endpoints: Anifrolumab serum concentration (Part A, up to Day 29), Cmax (maximum observed serum drug concentration) (Part A, up to Day 29) and 6 more. Started Dec 2024; status: recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2031240525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240525.